Ann: LBT Innovations Conference Call with CEO & MD Brent Barnes, page-25

Yesterday's edition of Bioshares rates LBT a BUY (Speculative class A).
They say machines will sell for $300,000 and pay for themselves within 2 years time. Also that BB believes we are at least 2 yrs ahead of competition and that our market is 12,000 medium-sized labs.
Regarding the news that Copan are working on similar technology. I don't think this is all bad news as it means this technology is definitely the way of the future. Also it remains to be seen how their technology compares (our patents might give us an advantage). It is the very large labs that currently use their automation technology. Admittedly, they have the advantage of greater resources to draw on, as they make money from selling swabs.